Top

Published in:

01-04-2011

Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

Author: Jennifer Spratlin

Published in: Current Oncology Reports | Issue 2/2011

Abstract

Angiogenesis, a well-recognized characteristic of malignancy, has been exploited more than any other pathway targeted by biologic anti-neoplastic therapies. Vascular endothelial growth factor receptor-2 (VEGFR-2) is the critical receptor involved in malignant angiogenesis with its activation inducing a number of other cellular modifications resulting in tumor growth and metastases. Ramucirumab (IMC-1121B; ImClone Systems Corporation, Branchburg, NJ) is a fully human monoclonal antibody developed to specifically inhibit VEGFR-2. Ramucirumab is currently being investigated in multiple clinical trials across a variety of tumor types. Herein, angiogenesis inhibition in cancer is reviewed and up-to-date information on the clinical development of ramucirumab is presented.

Hyder, S.M. and G.M. Stancel, Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol, 1999. 13(6): p. 806–11.PubMedCrossRef

Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995. 1(1): p. 27–31.PubMedCrossRef

Carmeliet, P. and R.K. Jain, Angiogenesis in cancer and other diseases. Nature, 2000. 407(6801): p. 249–57.PubMedCrossRef

Neufeld, G., T. Cohen, S. Gengrinovitch, et al., Vascular endothelial growth factor (VEGF) and its receptors. Faseb J, 1999. 13(1): p. 9–22.PubMed

Veikkola, T. and K. Alitalo, VEGFs, receptors and angiogenesis. Semin Cancer Biol, 1999. 9(3): p. 211–20.PubMedCrossRef

Li, B., G. Fuh, G. Meng, et al., Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization. J Biol Chem, 2000. 275(38): p. 29823–8.PubMedCrossRef

Gille, H., J. Kowalski, B. Li, et al., Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem, 2001. 276(5): p. 3222–30.PubMedCrossRef

Leung, D.W., G. Cachianes, W.J. Kuang, et al., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989. 246(4935): p. 1306–9.PubMedCrossRef

Lee, J.C., N.H. Chow, S.T. Wang, et al., Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer, 2000. 36(6): p. 748–53.PubMedCrossRef

10.

Kaya, A., A. Ciledag, B.E. Gulbay, et al., The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med, 2004. 98(7): p. 632–6.PubMedCrossRef

11.

Lecourtois, M., C. Alexandre, L. Dubois, et al., Wingless capture by Frizzled and Frizzled2 in Drosophila embryos. Dev Biol, 2001. 235(2): p. 467–75.PubMedCrossRef

12.

Plate, K.H., G. Breier, H.A. Weich, et al., Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer, 1994. 59(4): p. 520–9.PubMedCrossRef

13.

Witte, L., D.J. Hicklin, Z. Zhu, et al., Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev, 1998. 17(2): p. 155–61.PubMedCrossRef

14.

Zhu, Z. and L. Witte, Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs, 1999. 17(3): p. 195–212.PubMedCrossRef

15.

Zhu, Z., P. Bohlen, and L. Witte, Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets, 2002. 2(2): p. 135–56.PubMedCrossRef

16.

•• Gordon, M.S., K. Margolin, M. Talpaz, et al., Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol, 2001. 19(3): p. 843–50. This is a phase 1 study of bevacizumab.

17.

Holash, J., S. Davis, N. Papadopoulos, et al., VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 2002. 99(17): p. 11393–8.PubMedCrossRef

18.

Byrne, A.T., L. Ross, J. Holash, et al., Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res, 2003. 9(15): p. 5721–8.PubMed

19.

Huang, J., J.S. Frischer, A. Serur, et al., Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A, 2003. 100(13): p. 7785–90.PubMedCrossRef

20.

Fukasawa, M. and M. Korc, Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res, 2004. 10(10): p. 3327–32.PubMedCrossRef

21.

Tew, W.P., M. Gordon, J. Murren, et al., Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res, 2010. 16(1): p. 358–66.PubMedCrossRef

22.

Lockhart, A.C., M.L. Rothenberg, J. Dupont, et al., Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 28(2): p. 207–14.

23.

Chu, Q.S., Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther, 2009. 9(2): p. 263–71.PubMedCrossRef

24.

•• Awada, A., A. Hendlisz, T. Gil, et al., Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005. 92(10): p. 1855–61. This is a phase 1 study of sorafenib.

25.

•• Faivre, S., C. Delbaldo, K. Vera, et al., Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 2006. 24(1): p. 25–35. This is a phase 1 study of sunitinib.

26.

•• Britten, C.D., F. Kabbinavar, J.R. Hecht, et al., A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol, 2008. 61(3): p. 515–24. This is a phase 1 study of sunitinib.

27.

•• Strumberg, D., H. Richly, R.A. Hilger, et al., Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol, 2005. 23(5): p. 965–72. This is a phase 1 study of sorafenib.

28.

•• Moore, M., H.W. Hirte, L. Siu, et al., Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol, 2005. 16(10): p. 1688–94. This is a phase 1 study of sorafenib.

29.

Ton, N.C., G.J. Parker, A. Jackson, et al., Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res, 2007. 13(23): p. 7113–8.PubMedCrossRef

30.

Posey, J.A., T.C. Ng, B. Yang, et al., A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res, 2003. 9(4): p. 1323–32.PubMed

31.

Lu, D., X. Jimenez, H. Zhang, et al., Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer, 2002. 97(3): p. 393–9.PubMedCrossRef

32.

Imclone Systems Incorporated, Investigator’s Brochure. 2010.

33.

Lu, D., J. Shen, M.D. Vil, et al., Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem, 2003. 278(44): p. 43496–507.PubMedCrossRef

34.

Zhu, Z., K. Hattori, H. Zhang, et al., Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia, 2003. 17(3): p. 604–11.PubMedCrossRef

35.

•• Spratlin, J.L., R.B. Cohen, M. Eadens, et al., Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 28(5): p. 780–7. This is a phase 1 study of ramucirumab administered weekly.

36.

•• Chiorean, E., C. Sweeney, H. Hurwitz, et al., Phase I dose-escalation study of the anti-VEGFR-1 recombinant human IgG1 MAb IMC-1121B administered every other weeks (q2W) or every 3 (q3w) in patients (pts) with advanced cancers. Molecular Targets and Cancer Therapeutics, 2007. Conference Proceedings Abstract B15. This is a phase 1 study of ramucirumab administered every 2 or 3 weeks.

37.

•• Garcia, J.A., G.R. Hudes, T.K. Choueiri, et al. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/NCT00515697). in 2010 Genitourinary Cancers Symposium 2010. This is a phase 2 study of ramucirumab in RCC.

38.

•• Camidge, D.R., M.S. Ballas, S. Dubey, et al., A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010. 28:15s, 2010 (suppl; abstr 7588). This is a phase 2 study of ramucirumab in lung cancer.

39.

•• Carvajal, R.D., M.K. Wong, J.A. Thompson, et al., A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). J Clin Oncol 2010. 28:15s, 2010 (suppl; abstr 8519^) This is a phase 2 study of ramucirumab in malignant melanoma.

40.

•• Zhu, A.X., R.S. Finn, M. Mulcahy, et al. A phase 2 study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC): Updated results (CP12-0710/NCT00627042). in International Liver Cancer Association Fourth Annual Conference 2010. Montreal, Quebec, Canada. This is a phase 2 study of ramucirumab in HCC.

Title: Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2
Author: Jennifer Spratlin
Publication date: 01-04-2011
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 2/2011
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0149-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Commentary: Implications of Cancer Managed as a “Chronic Illness”

Changing the Perspective: Current Trends in the Assessment of Functional Outcome in Patients with Head and Neck Cancer

Sipuleucel-T: Prototype for Development of Anti-tumor Vaccines

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status

Endoscopic Resection of Sinonasal Malignancies

Biomarkers in Renal Cell Carcinoma: What Next?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer